Last updated: September 8, 2026
Nplate generated approximately $1 billion in annual sales for Amgen in the early 2020s, supported by chronic immune thrombocytopenia demand, limited direct biologic competition, and the 2021 U.S. approval for hematopoietic syndrome caused by radiation exposure. Its commercial outlook is stable but mature. Key risks are competition from oral thrombopoietin-receptor agonists, payer pressure, treatment switching, and eventual biosimilar or follow-on competition after regulatory and patent barriers weaken.
Nplate Market Dynamics, Financial Trajectory, Patent Position, and Competitive Outlook
What is Nplate and how does it work?
Nplate is the brand name for romiplostim, a recombinant thrombopoietin-receptor agonist marketed by Amgen. It is an injectable Fc-peptide fusion protein that stimulates megakaryocyte proliferation and platelet production.
The U.S. Food and Drug Administration approved Nplate in 2008 for adults with chronic immune thrombocytopenic purpura, now generally described as immune thrombocytopenia, who have had an insufficient response to other treatments. The FDA later expanded the label to include pediatric patients with chronic ITP and adults and children with hematopoietic syndrome caused by a myelosuppressive dose of radiation. [1]
Nplate is administered by subcutaneous injection, generally once weekly. The dose is adjusted according to platelet response, with the objective of reducing bleeding risk rather than normalizing platelet counts.
| Attribute |
Nplate |
| Active ingredient |
Romiplostim |
| Drug class |
Thrombopoietin-receptor agonist |
| Modality |
Peptide-Fc biologic |
| Initial U.S. approval |
2008 |
| Primary indication |
Chronic immune thrombocytopenia |
| Additional U.S. indication |
Hematopoietic syndrome of acute radiation syndrome |
| Administration |
Subcutaneous injection |
| U.S. reference product |
Yes |
| FDA regulatory pathway |
Biologics License Application |
| Commercial owner |
Amgen |
| Principal competitors |
Promacta, Doptelet, Tavalisse, IVIG, corticosteroids, splenectomy |
How has Nplate revenue developed?
Nplate has been one of Amgen’s durable specialty-care products. Public company filings indicate annual revenue of roughly $1 billion in recent years, with limited volatility compared with Amgen products exposed to biosimilar erosion.
| Fiscal year |
Approximate Nplate revenue |
Commercial interpretation |
| 2020 |
About $1.0 billion |
Mature chronic-therapy base |
| 2021 |
About $1.0 billion |
Stable demand despite pandemic disruption |
| 2022 |
About $1.0 billion |
Resilient specialty-care sales |
| 2023 |
About $1.1 billion |
Modest growth and continued international contribution |
| 2024 |
Approximately $1.1 billion, subject to final reporting classification |
Mature, relatively stable franchise |
Amgen reports product sales by brand in its annual filings, although reported figures can be affected by foreign-exchange movements, inventory changes, gross-to-net adjustments, and geographic reclassification. Nplate’s sales profile is materially different from that of Amgen’s large oncology and inflammatory brands. It is smaller in absolute scale but has a concentrated specialist prescriber base and lower exposure to direct small-molecule substitution.
The financial trajectory reflects three forces:
- Continued use in patients requiring durable platelet support.
- Increased competition from oral thrombopoietin-receptor agonists.
- Limited near-term erosion from approved biosimilars.
Nplate is therefore best characterized as a mature, cash-generative specialty biologic rather than a high-growth asset.
What drives Nplate market demand?
Chronic immune thrombocytopenia
Chronic ITP remains the core market. Patients may receive corticosteroids, IVIG, rituximab, splenectomy, fostamatinib, thrombopoietin-receptor agonists, or other therapies depending on disease duration, platelet count, bleeding history, comorbidities, treatment tolerance, and patient preference.
Nplate has several clinical and commercial advantages:
- Once-weekly dosing.
- Dose titration based on platelet response.
- Longstanding physician familiarity.
- Use in patients who have failed or cannot tolerate other therapies.
- A defined role in second-line or later-line treatment.
Its main disadvantage is the need for weekly injection and platelet monitoring. Oral competitors can be more convenient for some patients, although oral administration does not eliminate laboratory monitoring or safety management.
Hematopoietic syndrome of acute radiation syndrome
The FDA’s 2021 approval for hematopoietic syndrome of acute radiation syndrome expanded Nplate’s label beyond chronic ITP. The addressable patient population is small and event-driven, but the indication supports government procurement, emergency preparedness, and strategic stockpiling.
This indication is commercially different from ITP. It is unlikely to generate recurring high-volume prescription demand. Its value lies in procurement contracts, preparedness programs, and portfolio positioning in medical countermeasures.
Pediatric patients
Pediatric chronic ITP represents a smaller market than adult disease but provides an additional population under the FDA label. Pediatric use can support long-term brand familiarity and treatment persistence, although reimbursement and administration logistics remain important constraints.
How does Nplate compare with competing thrombopoietin-receptor agonists?
Nplate competes primarily with Promacta, Doptelet, and Tavalisse. Competition also comes from corticosteroids, IVIG, rituximab, splenectomy, and disease-specific supportive care.
| Product |
Active ingredient |
Route |
Key commercial distinction |
| Nplate |
Romiplostim |
Weekly subcutaneous injection |
Established injectable TPO-receptor agonist |
| Promacta |
Eltrombopag |
Oral |
Broad ITP and hematology indications; major incumbent competitor |
| Doptelet |
Avatrombopag |
Oral |
ITP and procedure-related thrombocytopenia positioning |
| Tavalisse |
Fostamatinib |
Oral |
SYK inhibitor for chronic ITP after prior treatment |
| IVIG |
Immunoglobulin |
Intravenous |
Rapid platelet support but episodic and resource-intensive |
Promacta, marketed by Novartis in the United States, has historically been Nplate’s most important branded competitor. Oral administration gives Promacta and Doptelet a convenience advantage, while Nplate retains a role for patients who respond well to injectable therapy or have clinical reasons to avoid oral alternatives.
The competitive balance is not determined solely by efficacy. Payers consider acquisition cost, administration cost, adherence, laboratory monitoring, bleeding outcomes, and the patient’s treatment history. Specialty pharmacies and infusion or injection networks also influence product selection.
What is the FDA regulatory status of Nplate?
Nplate is an FDA-approved biologic licensed under a Biologics License Application. Its approved U.S. uses include:
- Adult patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
- Pediatric patients at least one year of age with chronic ITP and insufficient response to other treatments.
- Adults and children with hematopoietic syndrome of acute radiation syndrome.
The product carries important warnings concerning risks such as thrombosis, bone marrow reticulin formation, loss of response, and platelet-count fluctuations. Long-term treatment requires clinical monitoring and dose adjustment under the prescribing information. [1]
Nplate is not an ordinary small-molecule generic product. The applicable U.S. regulatory framework is the Public Health Service Act, including the biosimilar pathway established by the Biologics Price Competition and Innovation Act.
What is the Orange Book status of Nplate?
Nplate is not principally an Orange Book product because the Orange Book covers approved drug products, while biologic reference products and biosimilar relationships are tracked through the FDA’s Purple Book.
The Purple Book identifies biologic reference products, biosimilars, and interchangeable biosimilars. As of the latest broadly reported public information through 2024, Nplate did not have an FDA-approved biosimilar or interchangeable biosimilar competitor. [2]
This distinction matters commercially:
- Nplate does not face ordinary Abbreviated New Drug Application substitution.
- A follow-on competitor would generally require a biosimilar or other biologic approval pathway.
- Pharmacy-level automatic substitution is more limited than for conventional generics.
- Patent disputes can still delay or complicate market entry.
When did Nplate lose biologic exclusivity?
Nplate’s 12-year U.S. reference-product exclusivity period was tied to its 2008 approval and generally ended in 2020. The expiration of exclusivity did not automatically produce biosimilar competition. A competitor still needs an approved application and must address patent, manufacturing, clinical, analytical, and commercial barriers.
Reference-product exclusivity and patent protection are separate. Exclusivity is a regulatory protection period. Patents can expire earlier or later depending on the patent family, patent-term adjustment, patent-term extension, pediatric extension, and claim scope.
Nplate’s commercial protection has therefore extended beyond its initial FDA exclusivity period through brand familiarity, manufacturing complexity, physician preference, regulatory barriers, and the absence of an approved biosimilar.
What patents protect Nplate?
Nplate’s principal intellectual-property value is associated with romiplostim composition, peptide-mimetic design, fusion-protein structure, production, formulation, and use. Public patent records contain multiple patent families and national-stage filings relating to thrombopoietin mimetics and their therapeutic use.
The relevant protection should be assessed by claim type rather than by a single headline expiration date:
| Protection category |
Commercial relevance |
| Composition claims |
Protect romiplostim or related peptide-Fc structures |
| Sequence and conjugation claims |
Protect active molecule architecture |
| Manufacturing claims |
Raise barriers to consistent biologic production |
| Formulation claims |
Protect stability, storage, and injectable presentation |
| Method-of-use claims |
Cover treatment of thrombocytopenia or related conditions |
| Regulatory exclusivity |
Delays biosimilar approval or reliance on the reference product |
A definitive patent-expiration analysis requires claim-by-claim review of issued U.S. patents, terminal disclaimers, patent-term adjustments, pediatric extensions, continuations, and litigation records. The absence of an Orange Book listing does not mean that Nplate lacks patent protection. It means the product’s biologic IP must be evaluated through patent databases, the Purple Book, FDA records, and court dockets.
Which companies are challenging Nplate?
No approved Nplate biosimilar competitor had established a U.S. commercial launch through 2024. The competitive challenge has instead come from companies selling alternative mechanisms or alternative thrombopoietin-receptor agonists.
The most relevant competitive companies include:
- Novartis, through Promacta or eltrombopag.
- Sobi, through Doptelet or avatrombopag in markets where it commercializes the product.
- Rigel Pharmaceuticals, through Tavalisse or fostamatinib.
- Generic and specialty pharmaceutical companies marketing corticosteroids, immunosuppressants, or supportive-care products.
A future biosimilar entrant would need to demonstrate high similarity to romiplostim, develop a scalable cell-based manufacturing process, secure regulatory approval, obtain reimbursement, and manage potential patent litigation.
What formulation and manufacturing barriers protect Nplate?
Nplate is a complex biologic rather than a conventional chemical tablet. Manufacturing barriers include:
- Recombinant production of the peptide-Fc molecule.
- Control of protein folding and aggregation.
- Batch-to-batch consistency.
- Potency and bioactivity testing.
- Sterility and aseptic filling.
- Stability during storage and distribution.
- Immunogenicity assessment.
- Clinical comparability for a biosimilar product.
The product’s subcutaneous presentation creates additional requirements for concentration, reconstitution, device compatibility, and administration. These factors can delay biosimilar entry even after core composition patents expire.
Manufacturing barriers are not absolute. Large biologic manufacturers can overcome them, but the required investment is higher than for a conventional generic drug. Commercial entry also depends on whether the market can support price discounts after development and litigation costs.
What patent litigation or settlement agreements affect Nplate?
Nplate has not experienced the level of public U.S. patent-litigation activity associated with major small-molecule blockbusters or high-volume biologics such as Humira. Publicly visible commercial risk has been driven more by therapeutic competition than by a disclosed biosimilar settlement framework.
No major Nplate-specific U.S. generic or biosimilar settlement has been broadly established as a central market event through 2024. This reduces near-term launch visibility for a challenger but does not eliminate future patent litigation risk.
A future dispute could involve:
- Romiplostim composition claims.
- Formulation and stability claims.
- Manufacturing-process claims.
- Therapeutic-use claims.
- Patent-listing and notice obligations under the biologics framework.
How strong is the Nplate patent estate?
Nplate’s patent estate is commercially meaningful but less durable than it was during the product’s early lifecycle. The strongest protections are likely to be the combination of biologic manufacturing complexity, regulatory barriers, clinical experience, and brand positioning rather than any single long-dated composition patent.
| Strength factor |
Assessment |
| Regulatory exclusivity |
Expired for the original U.S. approval period |
| Approved biosimilar competition |
No U.S. approval reported through 2024 |
| Manufacturing complexity |
Moderate to high |
| Physician familiarity |
High |
| Oral competitor pressure |
High |
| Dependence on a single indication |
Reduced by pediatric and radiation-syndrome labeling |
| Long-term growth potential |
Limited to moderate |
| Near-term erosion risk |
Low to moderate |
The estate is best viewed as a layered protection system. Patent strength alone is unlikely to support indefinite premium pricing, but the combination of technical barriers and specialist-market positioning can preserve revenue after formal exclusivity ends.
What generic or biosimilar launch scenarios exist for Nplate?
Scenario 1: No biosimilar launch in the near term
Nplate maintains approximately $1 billion in annual sales, supported by treatment persistence, specialist use, and limited direct substitution. This is the lowest-disruption scenario.
Scenario 2: One biosimilar launch
A single biosimilar could seek a moderate price discount and target large payer accounts or hospital systems. Revenue erosion would likely develop gradually because biologics are not automatically substituted in the same manner as small-molecule generics.
Scenario 3: Multiple biosimilar launches
Several entrants could trigger sharper net-price reductions, formulary exclusions, contracting pressure, and switching programs. The impact would depend on interchangeability, payer policies, physician confidence, and the number of approved competitors.
Scenario 4: Therapeutic substitution without biosimilar entry
Nplate could lose share to oral agents even without a biosimilar. This is the most immediate competitive risk because treatment decisions can change through formulary management, patient convenience, and new clinical evidence.
What is the geographic coverage of Nplate?
Nplate is marketed in the United States and multiple international markets under Amgen’s global commercial infrastructure. Regulatory labels differ by jurisdiction, particularly regarding pediatric use, chronic ITP treatment sequencing, and emergency-radiation indications.
International revenue is affected by:
- National reimbursement decisions.
- Hospital and specialist procurement.
- Reference-pricing systems.
- Currency movements.
- Local biosimilar policies.
- Distribution agreements.
- Different treatment guidelines.
The United States remains strategically important because of higher biologic pricing, while European and other developed markets generally apply stronger price controls and tender-based procurement.
What is the commercial outlook for Nplate?
Nplate’s base-case outlook is stable revenue with low-single-digit growth or decline depending on pricing, volume, and competitive switching. The product has a durable patient base, but the market is mature.
The principal revenue risks are:
- Oral competitor adoption.
- Payer-mandated sequencing.
- Net-price pressure.
- Reduced use after improved treatment persistence with alternatives.
- A future romiplostim biosimilar.
- Manufacturing or supply interruptions.
- Safety-related label changes.
The principal upside factors are:
- Greater use in pediatric ITP.
- Continued uptake in patients requiring long-term platelet support.
- Emergency-preparedness procurement for radiation syndrome.
- International expansion.
- Reduced use of competing therapies due to tolerability or adherence limitations.
Nplate is unlikely to return to a high-growth trajectory without a major new indication or a meaningful change in treatment guidelines. Its investment profile is stronger as a mature specialty asset with predictable demand than as an expansion-stage biologic.
Key Takeaways
- Nplate is Amgen’s romiplostim biologic for chronic immune thrombocytopenia and hematopoietic syndrome of acute radiation syndrome.
- Annual sales were approximately $1 billion in the early 2020s and reached roughly $1.1 billion in 2023.
- The U.S. 12-year reference-product exclusivity period associated with the 2008 approval ended around 2020.
- Nplate is tracked through the Purple Book framework rather than the conventional Orange Book generic-substitution system.
- No FDA-approved Nplate biosimilar had been broadly reported through 2024.
- Promacta, Doptelet, and Tavalisse are the most relevant branded competitive threats.
- Oral thrombopoietin-receptor agonists create more immediate commercial pressure than biosimilars.
- Manufacturing complexity, physician familiarity, and specialist prescribing support continued sales after formal exclusivity ended.
- The most likely financial trajectory is stable mature revenue with gradual competitive pressure rather than rapid growth or an abrupt patent cliff.
FAQs
Is Nplate a biologic or a generic drug?
Nplate is a biologic drug. Its active ingredient, romiplostim, is regulated under the biologics framework and would generally face biosimilar, rather than ordinary generic, competition.
Does Nplate have interchangeable biosimilar competition?
No FDA-approved interchangeable biosimilar for Nplate had been broadly reported through 2024.
Is Nplate more expensive than Promacta?
Pricing varies by dose, duration, payer, discounts, administration, and patient weight. Nplate is administered by injection, while Promacta is oral. A meaningful comparison must use total treatment cost rather than list price alone.
What is the largest threat to Nplate sales?
The largest near-term threat is therapeutic substitution toward oral agents such as eltrombopag and avatrombopag. A future biosimilar could create a larger pricing risk, but no approved U.S. biosimilar had established that pressure through 2024.
Can Nplate be used for radiation sickness?
Yes. The FDA approved Nplate for adults and children with hematopoietic syndrome associated with acute radiation syndrome. The indication is strategically important but is unlikely to generate recurring prescription volume comparable to chronic ITP.
References
- U.S. Food and Drug Administration. (2024). Nplate (romiplostim) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- Amgen Inc. (2021). 2020 annual report. https://www.amgen.com
- Amgen Inc. (2022). 2021 annual report. https://www.amgen.com
- Amgen Inc. (2023). 2022 annual report. https://www.amgen.com
- Amgen Inc. (2024). 2023 annual report. https://www.amgen.com
- U.S. Food and Drug Administration. (2021). FDA approves Nplate for treatment of hematopoietic syndrome of acute radiation syndrome in pediatric and adult patients. https://www.fda.gov
